Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies

 Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies

Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies

Shots:

  • The companies signed a license agreement to deploy TcBuster for the manufacturing of gene-modified cell therapies
  • Luminary gets a non-exclusive license for TcBuster and will use it in the LMY-920 program. Luminary plans to file an IND with the FDA in late 2021
  • The license agreement will allow Bio-Techne to increase its presence in the cell and gene therapy market

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Owler

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post